Review Article
Biomarkers of the Dementia
Table 2
Major studies of CSF biomarker to predict progression from MCI to AD published between 2004 and 2010.
| Study | Year | Case | Follow-up | MCI to AD | Marker | Sensitivity | Specificity | Other |
| Hampel | 2004 | 52 MCI 93 AD 10 cont | 8.4 M | 29/52 (56%) | Aβ42, †Tau | Aβ42 59% †Tau 83% | Aβ42 100% †Tau 90% | European cohort |
| Parnetti | 2006 | 55 MCI 100 AD 14 DLB 11 FTD
| 1 Y | 11/55 (20%) 38% of MCI has 2 marker abnormalities | Aβ42, †Tau, pTau181 | 2 biomarker abnormality in AD converters (91%) | Normal markers in stable MCI (88%) | Mayo Clinic Cohort |
| Hansson | 2006 | 137 MCI 39 cont | 4~7 Y | 57 AD (42%) 21 nonAD dementia (15%) 56 stable MCI (41%) | Aβ42, †Tau, pTau181 | Aβ42/†Tau 95% Aβ42/†Tau/ pTau181 95% | Aβ42/†Tau 83% Aβ42/†Tau/ pTau181 87% | Prospective study |
| Show | 2009 | 100 AD 191 MCI 114 cont | 1 Y | 37/191 (19%) | Aβ42, †Tau, pTau181 |
Tau/Aβ42 predicted 89% of AD converters CSF Aβ42 highly correlated with brain pathology | US-ADNI |
| Mattsson | 2009 | 750 MCI 529 AD 304 cont
| >2 Y | 271 AD/750 MCI (36%) 59 nonAD dementia/750 MCI | Aβ42, †Tau, pTau181 | 83% | 73% | 12 centers Europe/US |
| Visser | 2009 | 60 SCI 37 naMCI 71 aMCI 89 cont | 3 Y | 8/22 CSF/AD naMCI (36%) 27/53 CSF/AD aMCI (51%) | Aβ42, †Tau, pTau181 |
CSF/AD was observed in control 31%, SCI 52%, naMCI 68%, aMCI 79% All AD had CSF/AD CSF/AD is a significant risk in aMCI | DESCRIPA study Europe study |
|
|
SCI: subjective cognitive impairment; naMCI: nonamnesctic MCI; aMCI: amnestic MCI; CSF/AD: CSF AD profile (decreased Aβ42/increased tau).
|